Erectile Dysfunction Drug Could Become First Pill to Slow Alzheimer's

health

An erectile dysfunction drug is on the verge of becoming the first pill approved in the United States to slow Alzheimer's disease.

A lower-dose version of the South Korean drug Mvix, known experimentally as AR1001, slowed mental decline by roughly 31% over a yearlong trial of more than 1,500 people in the early stages of Alzheimer's.

The benefit appeared only in the 40% of participants who were not already taking other dementia medications, where memory, judgment, and daily functioning declined more slowly than in those given a placebo. Those already on dementia drugs saw little to no improvement, and across the full trial the overall effect fell short of statistical significance.

Side effects included diarrhea, dizziness, falls, and fainting. The developer, AriBio, plans to meet with the Food and Drug Administration to determine whether the results are strong enough or whether another trial is required.

The once-daily tablet, tested at 30 milligrams since late 2022, works differently from existing treatments by relaxing blood vessels to increase blood flow to the brain. Led by Stanford neurologist Sharon Sha, the findings were presented at the Clinical Trials on Alzheimer's Disease conference on Monday. If approved, the drug would give patients the first oral option capable of altering the disease rather than only easing its symptoms.